Ionis Pharmaceuticals: The Heartbreak Is Priced In
Seeking Alpha
Published: Jul 17, 2026, 07:09 AM GMT+9
Sentiment Analysis
The ATTR-CM and tominersen setbacks drove an excessive selloff without impairing Ionis’s wholly owned core assets.
Tryngolza is the main value driver, supported by strong triglyceride and pancreatitis data and a large sHTG market.
Dawnzera's upcoming pipeline catalysts and $1.9B of liquidity support growth and a credible path to 2028 breakeven.
Despite reimbursement, competition, and execution risks, Ionis’s ~$9B valuation offers attractive upside, supporting a speculative BUY.
I initiate coverage of Ionis Pharmaceuticals, Inc. (IONS) with a Buy rating.
Recently, the shares sold off following the two July 2026 setbacks: a) the phase 3 CARDIO-TTRansform trial of
Source: Seeking Alpha
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.